Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Short-bowel syndrome and intestinal failure

Gastroenterology and hepatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Escalate

Rigors, fever, hypotension or confusion during or after a parenteral infusion requires emergency sepsis assessment, appropriately timed paired line and peripheral cultures and immediate intestinal-failure or infection-team contact. High stoma output with oliguria, postural symptoms, rising creatinine or severe electrolyte disturbance requires urgent fluid and sodium replacement with specialist review.

Synopsis

Relate remaining bowel anatomy to fluid and nutrient loss, manage a high-output stoma without worsening sodium depletion, recognise line sepsis and intestinal-failure liver disease, and coordinate home parenteral support or teduglutide through a specialist centre.

  • Intestinal failure means gut function is insufficient to absorb macronutrients, water or electrolytes so intravenous supplementation is needed; short bowel is one anatomical cause.
  • Record the length and segment of remaining small bowel, whether colon is in continuity, ileocaecal valve, stoma and fistulae because these predict fluid and nutritional behaviour.
  • A jejunostomy with high output loses sodium-rich fluid; drinking large volumes of plain water or hypotonic drink can increase net sodium and water loss.
  • Use a high-sodium glucose oral rehydration solution in measured amounts, restrict hypotonic fluid under specialist advice and separate ordinary hydration advice from this physiology.
  • Dehydration presents with thirst, cramps, postural symptoms, low urine, rising creatinine and magnesium depletion; chronic episodes can cause irreversible kidney disease.
  • Fever, rigors or collapse during home parenteral infusion is catheter-related bloodstream infection until assessed urgently with paired line and peripheral cultures.
  • The colon salvages water and carbohydrate but increases enteric hyperoxaluria and renal-stone risk when fat malabsorption delivers oxalate to the colon.
  • Adaptation occurs over months to years; optimise diet, antimotility and antisecretory therapy before judging permanent parenteral needs or considering teduglutide.

Key red flags

High-output stoma dehydration

Output commonly above 1.5 to 2 litres daily with thirst, dizziness, low urine, cramps, weight loss, rising urea or creatinine and hypomagnesaemia suggests net intestinal fluid loss.

Catheter bloodstream infection

Rigors, fever, hypotension or confusion during or after infusion requires sepsis assessment, paired line and peripheral cultures and immediate intestinal-failure or infection contact.

Mechanical cause of output

Abruptly increased output with pain, fever, vomiting or inability to tolerate intake may represent infection, partial obstruction, recurrent disease or medication withdrawal rather than loss of adaptation.

Investigation priorities

01
Anatomical reconstructionFirst step

Retrieve operative records and contrast or cross-sectional imaging to document residual jejunum and ileum, colon continuity, valve, stoma, fistula and strictures.

Management branches

OutputHigh-output jejunostomy

Stoma output rises with thirst, falling urine, weight loss or biochemical depletion.

  1. Exclude obstruction, infection, recurrent disease and medicine withdrawal, then measure 24-hour oral intake, output, urine and weight.
  2. Replace intravenous sodium and magnesium when clinically depleted, and use the specialist high-sodium oral rehydration plan while limiting hypotonic fluid.
  3. Give antimotility treatment before food and antisecretory treatment when indicated, titrating under ECG and intestinal-failure guidance.
  4. Review anatomy, diet, sodium balance and need for parenteral fluid at frequent intervals until stable.
ChronicReduce parenteral dependence safely

Chronic short-bowel intestinal failure is clinically stable on an optimised regimen.

  1. Maximise oral diet, high-sodium fluid strategy, antimotility or antisecretory therapy and restore bowel continuity where feasible.
  2. Quantify stable parenteral needs and organ complications through a specialist intestinal-failure MDT.
  3. Consider teduglutide only when NICE eligibility and specialist safety screening are met, including neoplasia and obstruction review.
  4. Reduce parenteral volume gradually against urine, weight, electrolytes, renal function and nutrition rather than a predetermined target.

Key medicines

High-dose loperamideSpecialist doses given 30 to 60 minutes before meals and at night may exceed routine licensed limits in intestinal failure; follow the current BIFA ECG and prescribing guidance.High exposure can prolong QT and cause serious arrhythmia; obtain baseline and follow-up ECG as advised. Exclude obstruction and avoid casual over-the-counter escalation.
Proton pump inhibitorA current BNF oral or intravenous regimen selected for early gastric hypersecretion, absorption and ongoing output, then reviewed for continued need.Long-term hypomagnesaemia, infection, bone and medicine-interaction concerns. Benefit diminishes after adaptation in some patients, so reassess.
Open full textbook →Answer 2 questions
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • BIFA guidelines and position statementsCurrent home parenteral support, CRBSI, monitoring and high-dose loperamide guidance.
  • BSG short bowel guidelineAnatomy-specific fluid, diet and medicine physiology; marked under review and used with current BIFA guidance.
  • NICE TA804: TeduglutideUK eligibility for short-bowel syndrome treatment.
  • NICE CG32: Nutrition supportParenteral nutrition, monitoring and consent.
  • BNF: Antidiarrhoeal drugsCurrent prescribing safety context.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom